TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05263349

Intervention type: OTHER
Intervention: Typical Dreams Questionnaire
Description: Each of the dreams was classified according to its thematic content (e.g., being involved in a chase, flying through the air, falling, being lost, losing one's teeth, drowning) in order to in a chase, flying through the air, falling, being lost, losing teeth, drowning) in order to determine the most determine the most frequent themes emerging from our sample. The instrument used used to carry out this classification is the Typical Dream Questionnaire of Zadra and Nielsen (1999), which has been validated with more than 600 patients suffering from sleep disorders and and 1200 adults (Nielsen et al., 1999; 2003).

Intervention type: OTHER
Intervention: Typical Dreams Questionnaire
Description: Each of the dreams was classified according to its thematic content (e.g., being involved in a chase, flying through the air, falling, being lost, losing one's teeth, drowning) in order to in a chase, flying through the air, falling, being lost, losing teeth, drowning) in order to determine the most determine the most frequent themes emerging from our sample. The instrument used used to carry out this classification is the Typical Dream Questionnaire of Zadra and Nielsen (1999), which has been validated with more than 600 patients suffering from sleep disorders and and 1200 adults (Nielsen et al., 1999; 2003).

Intervention type: OTHER
Intervention: HAD Questionnaire
Description: The HAD scale is an instrument that screens for anxiety and depressive disorders. It includes 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D).~two scores (maximum score for each score = 21).

Intervention type: OTHER
Intervention: HAD Questionnaire
Description: The HAD scale is an instrument that screens for anxiety and depressive disorders. It includes 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D).~two scores (maximum score for each score = 21).

Intervention type: OTHER
Intervention: Dream Booklet
Description: The patient is asked to write down in a notebook every morning the description of the dreams made during the night and to comment on it if necessary

Intervention type: OTHER
Intervention: Dream Booklet
Description: The patient is asked to write down in a notebook every morning the description of the dreams made during the night and to comment on it if necessary
Study: NCT05603494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NuvoAir
Description: Use of NuvoAir in pulmonary function monitoring during asthma attack
Study: NCT05774613

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Effect of a Hibiscus sabdariffa beverage
Description: Hibiscus sabdariffa concentrate 60 mL from improved Mexican variety , administered on a single occasion

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Effect of a Hibiscus sabdariffa beverage
Description: Hibiscus sabdariffa concentrate 60 mL from improved Mexican variety , administered on a single occasion
Study: NCT04761952

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: azathioprine
Description: daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azathioprine
Description: daily orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: infliximab
Description: intravenously, at 0, 2,6 weeks with every 8-week-interval later
Study: NCT05772832

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: Efficacy of dexmedetomidine on postoperative pain in patients undergoing transsphenoidal pituitary surgery
Study: NCT04761952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infliximab
Description: intravenously, at 0, 2,6 weeks with every 8-week-interval later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-3 Polyunsaturated Fatty Acids
Description: Ethyl polyenoate capsule is given as drug intervention. The main components are ethyl eicosapentaenoate (EPA-E) and ethyl docosahexaenoate (DHA-E), both of which will transform into ethyl eicosapentaenoate (EPA) and ethyl docosahexaenoate (DHA). Drug dose is 0.25 g EPA-E\&DHA-E; per capsule one at a time, Three times a day.
Study: NCT01674738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 i.v. on day 1 (three-week cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 i.v. on day 1 (three-week cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 i.v. on day 1 (three-week cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 i.v. on day 1 (three-week cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7,5 mg/kg i.v. on day 1 (three-week cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7,5 mg/kg i.v. on day 1 (three-week cycle)
Study: NCT05772832

Intervention type: DRUG
Intervention: Remifentanyl
Description: Efficacy of remifentanyl on postoperative pain in patients undergoing transsphenoidal pituitary surgery
Study: NCT04579757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib and Tislelizumab _ Part 1
Description: Part 1 (all cohorts): oral surufatinib at a dose based on cohort level and intravenous tislelizumab at a 200-mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib and Tislelizumab _ Part 2
Description: Part 2 (all cohorts): oral surufatinib at the RP2D dose selected in Part 1 and intravenous tislelizumab at a 200-mg dose
Study: NCT06074068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fathers for Change
Description: 18 week individual therapy focused on fathers' emotion regulation, reflective functioning and family communication.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Duluth BIP
Description: 18 week individually delivered psychoeducation and CBT focused program focused on intimate partner violence
Study: NCT05349175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Infant Resuscitator (AIR)
Description: Real-time visual feedback from the AIR device regarding quality of bag-mask ventilation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Infant Resuscitator (AIR)
Description: Real-time visual feedback from the AIR device regarding quality of bag-mask ventilation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Infant Resuscitator (AIR)
Description: Real-time visual feedback from the AIR device regarding quality of bag-mask ventilation
Study: NCT05746871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Agilik
Description: The Agilik is a powered orthosis system that can assist or resist motion independently in each gait phase. It is used as a pair of knee-ankle-foot orthosis (KAFO), one for each leg. The device applies up to 12 Nm across the knee in the direction of either flexion or extension. The system consists of an orthosis for each leg integrated with an electro-mechanical actuator, a battery, a carry pack, cabling and application software running on a computer. A foot pressure sensor is embedded in the footbed of the KAFO and connected to the actuator. The foot sensor and angular velocity are used to detect the gait phase of the patient and communicate with the motor controller to provide a unique torque for each gait phase. The torque ramp and intensity can be modified through the Agilik App to cater towards individual patients by assisting or resisting motion during their gait. This allows for the clinician working with the patient to adjust the settings of the device for the patient's needs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Agilik
Description: The Agilik is a powered orthosis system that can assist or resist motion independently in each gait phase. It is used as a pair of knee-ankle-foot orthosis (KAFO), one for each leg. The device applies up to 12 Nm across the knee in the direction of either flexion or extension. The system consists of an orthosis for each leg integrated with an electro-mechanical actuator, a battery, a carry pack, cabling and application software running on a computer. A foot pressure sensor is embedded in the footbed of the KAFO and connected to the actuator. The foot sensor and angular velocity are used to detect the gait phase of the patient and communicate with the motor controller to provide a unique torque for each gait phase. The torque ramp and intensity can be modified through the Agilik App to cater towards individual patients by assisting or resisting motion during their gait. This allows for the clinician working with the patient to adjust the settings of the device for the patient's needs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care
Description: Subjects will continue with their standard care for 5 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care
Description: Subjects will continue with their standard care for 5 weeks
Study: NCT05693558

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVD-003, an autologous 3D scaffold free osteogenic graft
Description: Bone correction and grafting surgery
Study: NCT06378476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPaCT Community Health Worker Program
Description: The IMPaCT intervention consists of three stages: goal-setting, tailored support, and connection with long-term support. CHWs first seek to understand the patient's individual circumstances, life histories, and priorities by using a semi-structured interview guide inquiring about social and behavioral determinants of health. CHWs will then partner with patients to create customized action plans based on patient needs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trauma-Informed Care Training
Description: Primary care providers and staff at two General Internal Medicine clinics will receive training in providing supportive care to patients who have experienced trauma. The trainings are all action focused and include a review of racism in medicine, understanding intergenerational trauma and its impact on care, naming and mitigating barriers to health equity, and the basics of motivational interviewing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trauma-Informed Care Training
Description: Primary care providers and staff at two General Internal Medicine clinics will receive training in providing supportive care to patients who have experienced trauma. The trainings are all action focused and include a review of racism in medicine, understanding intergenerational trauma and its impact on care, naming and mitigating barriers to health equity, and the basics of motivational interviewing
Study: NCT06103123

Intervention type: DIAGNOSTIC_TEST
Intervention: Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire
Description: Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives

Intervention type: DIAGNOSTIC_TEST
Intervention: Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire
Description: Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives

Intervention type: DIAGNOSTIC_TEST
Intervention: Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire
Description: Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives

Intervention type: DIAGNOSTIC_TEST
Intervention: Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire
Description: Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives

Intervention type: OTHER
Intervention: Baseline Quality of Life questionnaire
Description: Only baseline quality of life questionnaires will be utilized in the alternative etiology myocarditis cohort as they will not be followed up in the study
Study: NCT05226715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chiropractic manual therapy
Description: high velocity low amplitude thrust into a human joint
Study: NCT04438304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-SARTATE
Description: 64Cu-SARTATE will be administered at a fixed administration dose, single bolus intravenous injection, peptide mass not exceeding 60µg.
Study: NCT06434025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Carboxymaltose
Description: Iron Carboxymaltose 500 mg. 2 vials administered IV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Carboxymaltose
Description: Iron Carboxymaltose 500 mg. 2 vials administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10mg Tab, PO, onde a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Iron Carboxymaltose
Description: Solution Sodium Chloride 0,9% 100 ml, IV, once.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Dapagliflozin
Description: Equal shape and appearance tab as the tab containing Dapagliflozin 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Dapagliflozin
Description: Equal shape and appearance tab as the tab containing Dapagliflozin 10 mg
Study: NCT04738604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany
Description: The prepared cavities will be restored with Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 20 seconds according to manufacturer's instructions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany
Description: The prepared cavities will be restored with Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 20 seconds according to manufacturer's instructions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany)
Description: The prepared cavities will be restored with Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 40 seconds according to manufacturer's instructions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany)
Description: The prepared cavities will be restored with Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 40 seconds according to manufacturer's instructions.
Study: NCT04949828

Intervention type: DRUG
Intervention: CREON
Description: Oral Capsules
Study: NCT06633419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered at a dose of 5 mg or 10 mg dependent on HRT dosing regimen via oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered at a dose of 5 mg or 10 mg dependent on HRT dosing regimen via oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone acetate
Description: Administered at a dose of 0.05 mg or 0.1 mg dependent on HRT dosing regimen via oral tablets.
Study: NCT05778929

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiomics Model
Description: A total of 694 consecutive eligible patients with first episode of acute pancreatitis that recommended for iopromide 370 mgI/ml enhanced pancreatic CT scan within 14 days after onset of symptoms (the sample size ratio of training set: test set: validation set is 5:2:3) will be sequentially enrolled at 10 sites (This study is observational in nature. The routine enhanced pancreatic CT protocol at all selected sites is similar or equivalent to that used in the PI site in the study).~Relevant clinical information of the enrolled subjects is collected. Radiomics features are extracted from the selected regions of interest on pancreatic CT images and classified. The subjects are followed up for 12 months and divided into recurrent group and non-recurrent group according to the first recurrence status.
Study: NCT06633419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone acetate
Description: Administered at a dose of 0.05 mg or 0.1 mg dependent on HRT dosing regimen via oral tablets.
Study: NCT05250466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency technology
Description: The vulva and vagina were routinely disinfected with iodophor, the negative plate was placed on the patient's waist and abdomen, and the vulva module was selected for treatment for 10 minutes per side, for a total of 20 minutes. Parameters: power 10-20W, temperature 38-42C°, once every 10 days, 5 times in total

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulation
Description: Routine vulvovaginal disinfection with iodophor, vaginal probes are placed in channel A, electrode pads are placed in channels B\\C\\D respectively, the frequency of electrical stimulation (the most comfortable amount) is adjusted, 10 times is a course of treatment, and mild lesions are treated for 1-2 courses of treatment , 2 to 3 courses of treatment for moderate to severe lesions.
Study: NCT06633419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Administered at a dose of 100 mg, 200 mg, or 300 mg BID dependent on dosing regimen via oral capsule (extended-release).
Study: NCT05644015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: escape room game
Description: Escape room game is a live action team based game where players discover clues, solve puzzles and complete tasks in one or more rooms to accomplish a specific goal (usually by escaping the room) in limited time.
Study: NCT05814627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib Matching Placebo
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Matching Placebo
Description: Subcutaneous Injection
Study: NCT04793685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: Prazosin (16mg/day) versus Placebo comparator, with a 2 week titration period, 9 weeks at full dose and a 5-day taper in week 12.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-Step Facilitation with Relapse Prevention and Contingency Management
Description: 12-Step Facilitation and relapse prevention weekly support and Contingency Management with vouchers for each weekly appointment to support treatment attendance for all subjects.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 12-Step Facilitation with Relapse Prevention and Contingency Management
Description: 12-Step Facilitation and relapse prevention weekly support and Contingency Management with vouchers for each weekly appointment to support treatment attendance for all subjects.
Study: NCT06334120

Intervention type: DRUG
Intervention: Darolutamide (Nubeqa, BAY1841788)
Description: The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.
Study: NCT05964335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine ER 27 mg
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine ER 54 mg
Description: Oral Tablets
Study: NCT05964335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine ER 108 mg
Description: Oral tablets
Study: NCT06206200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive dual task training (intervention group)
Description: Simultaneously performing cognitive tasks and motor rehabilitative exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care physiotherapy (control group)
Description: The current best physical therapy treatment for patients with anterior cruciate ligament reconstruction based on existing scientific evidence.
Study: NCT06238011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine(Precedex Pfizer) prepared in concentration 0.1 mcg/kg/ml total volume50 ml by nurse anesthetist at preprocedure room, start dexmedetomidine by anesthesiologist at operating room loading 60 ml/hour for 10 minutes before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass (loading 1mcg/kg in 10 minutes then 0.5 mcg/kg/hour). Record patients data by nurse anesthetist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal Saline total volume50 ml prepared by nurse anesthetist at preprocedure room, start Normal Saline by anesthesiologist at operating room loading 60 ml/hour for 10 minutes before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass. Record patients data by nurse anesthetist
Study: NCT05355181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scar mobilization techniques
Description: Scar mobilization techniques include the gentle stroking and lifting of the scar as well as moving the scar tissue in different directions. It also includes rolling, C- grip, S-grip, and ram horn mobilization of the scar tissue.~Core stabilization exercises administered after cesarean section include the posture corrective exercises, abdominal draw-in, squatting, pelvis tilting, knee to chest, flexibility and stretching exercises, and bridges.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scar mobilization techniques
Description: Scar mobilization techniques include the gentle stroking and lifting of the scar as well as moving the scar tissue in different directions. It also includes rolling, C- grip, S-grip, and ram horn mobilization of the scar tissue.~Core stabilization exercises administered after cesarean section include the posture corrective exercises, abdominal draw-in, squatting, pelvis tilting, knee to chest, flexibility and stretching exercises, and bridges.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stabilization exercises
Description: Core stabilization exercises
Study: NCT04974190

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Spray Device
Description: A Nasal Spray apparatus containing a liquid

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Spray Device
Description: A Nasal Spray apparatus containing a liquid
Study: NCT05559866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo ESG with ERBE HAPC
Description: Utilizing two approved devices in combination to assess durability of suturing.